Everand Logo

Welcome to Everand!

  • STAT

    Opinion: Early treatment with gene therapy: lessons from vaccines

    by Jeremy Schafer Apr 24, 2019 4 minutes
    Early intervention, a standard approach for vaccines, may also be useful as gene therapy takes off.

    The concept of modifying the human genome to treat or cure disease was once the stuff of science fiction. Today there are products on the market to do just that. This amazing leap has come with a hefty price tag. Currently marketed gene therapies hover around $500,000 or more per course of therapy and future agents may top $3 million to treat a single patient.

    Providers and payers must ask themselves a two-pronged question about gene therapy: Who should be treated and when?

    agents such as including Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) reprogram the genes of cancer-fighting cells to combat diseases like leukemia. (voretigene neparvovec-rzyl)‎ treats a congenital eye disorder that results in blindness. Other diseases that may have therapies available in the next few

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min readChemistry
    STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
    Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

    Related Books & Audiobooks